The American Medical Association (AMA) recently added a new CPT code that will be used to report a COVID-19 vaccine candidate under development by Janssen Pharmaceutica, a division of Johnson & Johnson.
The new CPT code is:
- 91303, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular use
The AMA also created a new HCPCS Level II code for the vaccine’s administration:
- 0031A, immunization administration by intramuscular injection of SARS-CoV-2 (COVID-19) vaccine, DNA, spike protein, Ad26 vector, preservative free, 5×1010 viral particles/0.5 mL dosage, single dose
These codes will go into effect when the Food and Drug Administration approves the vaccine candidate or grants it emergency use authorization, according to the AMA.
For More Information: https://www.healthleadersmedia.com/revenue-cycle/ama-announces-new-cpt-code-johnson-johnsons-covid-19-vaccine
